|
293 Companies |
|
490 Products |
|
490 Products |
|
199 Mechanisms of Action |
|
25 Trials |
|
7787 News |
|
| «12...7879808182838485868788...156157» |
- insulin peglispro (LY2605541) / Eli Lilly
Enrollment closed: A Study of Insulin Peglispro and Glargine on Fats in Participants With Type 1 Diabetes (clinicaltrials.gov) - Dec 6, 2014
P1, N=18, Active, not recruiting, Sponsor: Eli Lilly and Company
Recruiting --> Active, not recruiting
- Enrollment closed, Trial initiation date, Trial primary completion date: Educational Efficacy Assessment of a Serious Game to Teach Insulin Therapy to Primary Care Physicians (clinicaltrials.gov) - Dec 6, 2014
P=N/A, N=160, Active, not recruiting, Sponsor: Universidade Estadual de Londrina
Recruiting --> Active, not recruiting Not yet recruiting --> Active, not recruiting | Initiation date: Jun 2013 --> Jul 2014 | Trial primary completion date: Dec 2013 --> Apr 2015
- ||| Enbrel (etanercept) / Pfizer, Amgen, Humira (adalimumab) / AbbVie, Rituxan (rituximab) / Roche
Enrollment closed, Trial primary completion date: ORBIT: Optimal Management of Rheumatoid Arthritis Patients Requiring Biologic Therapy (clinicaltrials.gov) - Dec 6, 2014
P4, N=302, Active, not recruiting, Sponsor: University of Glasgow
Not yet recruiting --> Active, not recruiting | Initiation date: Jun 2013 --> Jul 2014 | Trial primary completion date: Dec 2013 --> Apr 2015 Recruiting --> Active, not recruiting | Trial primary completion date: Jun 2014 --> Dec 2014
- Lantus (insulin glargine) / Sanofi
Trial completion: Health Care for Type 1 Diabetes in Developing World (clinicaltrials.gov) - Dec 6, 2014
P=N/A, N=50, Completed, Sponsor: University of Pittsburgh
Recruiting --> Active, not recruiting | Trial primary completion date: Jun 2014 --> Dec 2014 Recruiting --> Completed
- Trial completion, Enrollment change, Trial primary completion date: FTO_T1DM: The Role of FTO Gene Polymorphism and Insulin Preparation in Obesity in Children With Type 1 Diabetes Mellitus (clinicaltrials.gov) - Dec 6, 2014
P=N/A, N=2000, Completed, Sponsor: University of Bialystok
Recruiting --> Completed Recruiting --> Completed | N=3000 --> 2000 | Trial primary completion date: Jun 2011 --> Dec 2014
- Enrollment change, Trial termination, Trial primary completion date, MRI: Leflunomide Versus Sulfasalazine/Methotrexate in Rheumatoid Arthritis:an Ultrasound/Magnetic Resonance Imaging Study (clinicaltrials.gov) - Dec 5, 2014
P4, N=1, Terminated, Sponsor: Singapore General Hospital
Recruiting --> Completed | N=3000 --> 2000 | Trial primary completion date: Jun 2011 --> Dec 2014 N=20 --> 1 | Recruiting --> Terminated | Trial primary completion date: Dec 2013 --> Dec 2012
- Clinical: Centralized Reading Assessment of Chronic CerebroSpinal Venous Insufficiency (CCSVI) in Patients With Multiple Sclerosis and Other Neurological Diseases (clinicaltrials.gov) - Dec 5, 2014
P=N/A, N=499, Enrolling by invitation, Sponsor: University at Buffalo
- ||| Enrollment open: TC-A Registration Study (clinicaltrials.gov) - Dec 5, 2014
P=N/A, N=156, Recruiting, Sponsor: Smith & Nephew Medical (Shanghai) Ltd
N=20 --> 1 | Recruiting --> Terminated | Trial primary completion date: Dec 2013 --> Dec 2012 Not yet recruiting --> Recruiting
- ||||| Hadlima (adalimumab-bwwd) / Organon, Biogen, Samsung, Mundipharma, Yuhan Corp
Enrollment closed: A Study Comparing SB5 to Humira® in Subjects With Moderate to Severe Rheumatoid Arthritis Despite Methotrexate Therapy (clinicaltrials.gov) - Dec 5, 2014
P3, N=490, Active, not recruiting, Sponsor: Samsung Bioepis Co., Ltd.
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- Enrollment closed, Trial primary completion date, Adherence: Development of a Motivational Intervention to Improve Treatment Adherence in MS (clinicaltrials.gov) - Dec 5, 2014
P=N/A, N=80, Active, not recruiting, Sponsor: University of Missouri, Kansas City
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting | Trial primary completion date: Oct 2014 --> Feb 2015
- Trial completion, Enrollment change, Trial primary completion date: The Effects of Ankle Foot Orthoses (AFOs) on Mobility in Persons With Multiple Sclerosis (MS) (clinicaltrials.gov) - Dec 5, 2014
P=N/A, N=2, Completed, Sponsor: University of Texas Southwestern Medical Center
Recruiting --> Active, not recruiting | Trial primary completion date: Oct 2014 --> Feb 2015 Recruiting --> Completed | N=15 --> 2 | Trial primary completion date: Sep 2014 --> Dec 2014
- | Trial completion, Enrollment change, Trial primary completion date: Multiple Sclerosis and Progressive Resistance Training (clinicaltrials.gov) - Dec 5, 2014
P=N/A, N=35, Completed, Sponsor: University of Aarhus
Recruiting --> Completed | N=15 --> 2 | Trial primary completion date: Sep 2014 --> Dec 2014 Active, not recruiting --> Completed | N=80 --> 35 | Trial primary completion date: Aug 2013 --> Jan 2014
- | Tysabri (natalizumab) / Biogen, Royalty
Trial completion, Enrollment change: The Effect of Natalizumab (Tysabri) on Sexual Dysfunction in Multiple Sclerosis (clinicaltrials.gov) - Dec 5, 2014
P=N/A, N=45, Completed, Sponsor: University of South Florida
Active, not recruiting --> Completed | N=80 --> 35 | Trial primary completion date: Aug 2013 --> Jan 2014 Recruiting --> Completed | N=30 --> 45
- Trial primary completion date: IFOPI: Evaluation of Functional Insulin Therapy in Type 1 Diabetic Patients (clinicaltrials.gov) - Dec 5, 2014
P2, N=60, Recruiting, Sponsor: University Hospital, Montpellier
Recruiting --> Completed | N=30 --> 45 Trial primary completion date: May 2014 --> Jan 2015
- Trial primary completion date: To Evaluate if Wide Blood Sugar Fluctuations Lead to Injury of Heart Function and Heart Nerves (clinicaltrials.gov) - Dec 5, 2014
P=N/A, N=55, Recruiting, Sponsor: University of Michigan
Trial primary completion date: May 2014 --> Jan 2015 Trial primary completion date: Jan 2014 --> Jan 2016
- Enrollment change, Trial termination, MRI: Islet of Langerhans Graft Monitoring by Magnetic Resonance Imaging (clinicaltrials.gov) - Dec 5, 2014
P1, N=5, Terminated, Sponsor: University Hospital, Geneva
Trial primary completion date: Jan 2014 --> Jan 2016 N=15 --> 5 | Recruiting --> Terminated; Feasibility issues
- Clinical: The Role of Endogenous Lactate in Brain Preservation and Counterregulatory Defenses Against Hypoglycemia (clinicaltrials.gov) - Dec 5, 2014
P=N/A, N=30, Not yet recruiting, Sponsor: Radboud University
- Enrollment open: Safety of FURESTEM-RA Inj. in Patients With Moderate to Severe Rheumatoid Arthritis(RA) (clinicaltrials.gov) - Dec 5, 2014
P1, N=9, Recruiting, Sponsor: Kang Stem Biotech Co., Ltd.
N=15 --> 5 | Recruiting --> Terminated; Feasibility issues Not yet recruiting --> Recruiting
- Enrollment closed: Hybrid Artificial Pancreas in Home Setting (clinicaltrials.gov) - Dec 5, 2014
P2, N=36, Active, not recruiting, Sponsor: University Hospital, Montpellier
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- Trial completion: Short Term Closed-loop Glucose Control in Adults With Type 1 Diabetes (clinicaltrials.gov) - Dec 5, 2014
P2, N=18, Completed, Sponsor: University of Cambridge
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- ||| Trial completion, Trial primary completion date, Surgery: A Prospective Randomized Equivalence Trial to Evaluate the Safety of the Ligasure in Thyroid Surgery (clinicaltrials.gov) - Dec 5, 2014
P=N/A, N=96, Completed, Sponsor: University of Alberta
Active, not recruiting --> Completed Recruiting --> Completed | Trial primary completion date: Dec 2011 --> Sep 2012
- GZ402668 / Sanofi
Enrollment open: A First-in-human, Single Ascending Dose Study of GZ402668 in Patients With Progressive Multiple Sclerosis (clinicaltrials.gov) - Dec 4, 2014
P1, N=48, Recruiting, Sponsor: Genzyme, a Sanofi Company
Recruiting --> Completed | Trial primary completion date: Dec 2011 --> Sep 2012 Not yet recruiting --> Recruiting
- icanbelimod (CBP-307) / Suzhou Connect Biopharma
Enrollment open: Phase 1 Study Accessing the Safety and Tolerability of CBP-307 (clinicaltrials.gov) - Nov 30, 2014
P1, N=64, Recruiting, Sponsor: Suzhou Connect Biopharmaceuticals, Ltd.
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- Clinical: Step it Up: An Exercise and Behaviour Change Programme for People With Multiple Sclerosis (clinicaltrials.gov) - Nov 28, 2014
P=N/A, N=72, Recruiting, Sponsor: University of Limerick
- ||||| tabalumab (LY2127399) / Eli Lilly
Enrollment closed: A Study of Tabalumab (LY2127399) Using Two Different Injection Methods in Participants With Lupus (clinicaltrials.gov) - Nov 28, 2014
P3, N=216, Active, not recruiting, Sponsor: Eli Lilly and Company
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- || Enrollment closed, Trial primary completion date: Study of Subtalar Arthrodesis Using AlloStem® Versus Autologous Bone Graft (clinicaltrials.gov) - Nov 28, 2014
P=N/A, N=140, Active, not recruiting, Sponsor: AlloSource
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting | Trial primary completion date: May 2014 --> Feb 2017
- mycophenolate mofetil / Generic mfg.
Trial primary completion date: Comparison Between Tacrolimus (TAC) and Mycophenolate Mofetil (MMF) for Induction of Remission in Lupus Nephritis (clinicaltrials.gov) - Nov 28, 2014
P=N/A, N=90, Recruiting, Sponsor: Ramathibodi Hospital
Recruiting --> Active, not recruiting | Trial primary completion date: May 2014 --> Feb 2017 Trial primary completion date: Dec 2014 --> Dec 2015
- | Enbrel (etanercept) / Pfizer, Amgen
Phase classification: ANTIBODY-RA: Drug Concentration, Immunogenicity, and Efficacy Study in Patients With Rheumatoid Arthritis Currently Treated With Etanercept, Adalimumab, or Infliximab (clinicaltrials.gov) - Nov 28, 2014
P4, N=600, Recruiting, Sponsor: Pfizer
Trial primary completion date: Dec 2014 --> Dec 2015 Phase classification: P=N/A --> P4
- ||| Clinical: Aggressive Onset Multiple Sclerosis: A Practical Definition and Study of Its Clinical Course (clinicaltrials.gov) - Nov 28, 2014
P=N/A, N=750, Active, not recruiting, Sponsor: Weill Medical College of Cornell University
- |||||| Farxiga (dapagliflozin) / Ono Pharma, AstraZeneca
Enrollment open: DEPICT 1: Dapagliflozin Evaluation in Patients With Inadequately Controlled Type 1 Diabetes (clinicaltrials.gov) - Nov 28, 2014
P3, N=768, Recruiting, Sponsor: Bristol-Myers Squibb
Phase classification: P=N/A --> P4 Not yet recruiting --> Recruiting
- |||| Actemra SC (tocilizumab SC) / Roche, Halozyme
Trial primary completion date: COMP-ACT: A Study of the Impact of Methotrexate (MTX) Discontinuation on the Efficacy of Subcutaneous (SC) Tocilizumab (TCZ) With MTX (clinicaltrials.gov) - Nov 25, 2014
P3, N=600, Recruiting, Sponsor: Hoffmann-La Roche
Not yet recruiting --> Recruiting Trial primary completion date: Aug 2016 --> Feb 2016
- Enrollment open: Developing and Testing a Comprehensive MS Spasticity Management Program (clinicaltrials.gov) - Nov 25, 2014
P2, N=50, Enrolling by invitation, Sponsor: Department of Veterans Affairs
Trial primary completion date: Aug 2016 --> Feb 2016 Not yet recruiting --> Enrolling by invitation
- ||| Betaseron (IFN-β-1b) / Bayer
Enrollment open, Adherence: BETAEVAL Global - The New BETACONNECT Auto-injector : Adherence and EVALuation of Multiple Sclerosis Patients Treated With Betaferon (clinicaltrials.gov) - Nov 25, 2014
P=N/A, N=450, Recruiting, Sponsor: Bayer
Not yet recruiting --> Enrolling by invitation Not yet recruiting --> Recruiting
- |||| Rebif (human IFN-β-1a) / EMD Serono
Enrollment open: RESOunD: REbif Satisfaction On Discontinuing Oral Dimethyl Fumarate (clinicaltrials.gov) - Nov 25, 2014
P4, N=90, Recruiting, Sponsor: EMD Serono
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- Trial completion, Enrollment change: FARMS-2: Fall Risk Reduction in Multiple Sclerosis: Exercise Versus Behavior (clinicaltrials.gov) - Nov 25, 2014
P1/2, N=37, Completed, Sponsor: University of Illinois at Urbana-Champaign
Not yet recruiting --> Recruiting Active, not recruiting --> Completed | N=60 --> 37
- | Actemra IV (tocilizumab) / Roche, JW Pharma
Trial primary completion date: A Long-Term Extension Study to WA19926 (NCT01007435) of Tocilizumab in Participants With Early, Moderate to Severe Rheumatoid Arthritis (clinicaltrials.gov) - Nov 25, 2014
P3, N=38, Active, not recruiting, Sponsor: Hoffmann-La Roche
Active, not recruiting --> Completed | N=60 --> 37 Trial primary completion date: Feb 2015 --> Aug 2015
- Trial termination, Trial primary completion date: Choroidal Blood Flow Changes During Dark/Light Transitions in Patients With Insulin-dependent Diabetes Mellitus (IDDM) (clinicaltrials.gov) - Nov 25, 2014
P=N/A, N=80, Terminated, Sponsor: Medical University of Vienna
Trial primary completion date: Feb 2015 --> Aug 2015 Recruiting --> Terminated | Trial primary completion date: Jan 2009 --> Jul 2007
- || Actemra IV (tocilizumab) / Roche, JW Pharma
Enrollment closed: An Global Comparative Observational Study of RoActemra/Actemra (Tocilizumab) in Patients With Rheumatoid Arthritis (clinicaltrials.gov) - Nov 25, 2014
P=N/A, N=1232, Active, not recruiting, Sponsor: Hoffmann-La Roche
Recruiting --> Terminated | Trial primary completion date: Jan 2009 --> Jul 2007 Completed --> Active, not recruiting
- || Xeljanz (tofacitinib) / Pfizer
Clinical: A Study to Assess Immune Response Following Zoster Vaccination to Subjects With Rheumatoid Arthritis Receiving Tofacitinib or Placebo With Background Methotrexate (clinicaltrials.gov) - Nov 24, 2014
P2, N=140, Recruiting, Sponsor: Pfizer
Completed --> Active, not recruiting Trial primary completion date: Apr 2015 --> Jul 2015
- Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
Enrollment open, P1 data, MRI: A Phase 1 Trial of Intrathecal Rituximab for Progressive Multiple Sclerosis Patients (clinicaltrials.gov) - Nov 24, 2014
P1, N=12, Recruiting, Sponsor: Johns Hopkins University
Trial primary completion date: Apr 2015 --> Jul 2015 Not yet recruiting --> Recruiting
- Trial primary completion date: A Survey on Hypoglycaemia Among Insulin-treated Patients With Diabetes (clinicaltrials.gov) - Nov 23, 2014
P=N/A, N=675, Enrolling by invitation, Sponsor: Novo Nordisk A/S
Not yet recruiting --> Recruiting Trial primary completion date: Jan 2015 --> Apr 2015
- Biomarker, Enrollment closed: Evaluation of Biomarker Expression in Diabetic and Healthy Subjects Over a One Year Period (clinicaltrials.gov) - Nov 23, 2014
P=N/A, N=60, Active, not recruiting, Sponsor: Novo Nordisk A/S
Trial primary completion date: Jan 2015 --> Apr 2015 Enrolling by invitation --> Active, not recruiting
- | methylprednisolone sodium succinate / Generic mfg.
Clinical: A Randomized Study of IVIG vs. IVIG With High Dose Methylprednisolone in Childhood ITP. (clinicaltrials.gov) - Nov 20, 2014
P3, N=36, Recruiting, Sponsor: The Hospital for Sick Children
Enrolling by invitation --> Active, not recruiting Trial primary completion date: Dec 2014 --> Dec 2015
- fletikumab (NNC109-0012) / Novo Nordisk
Trial termination: A Trial of NNC0109-0012, an Anti-IL-20 Biologic, in Patients With Active Rheumatoid Arthritis Who Are Inadequate Responders to Methotrexate (clinicaltrials.gov) - Nov 20, 2014
P2, N=298, Terminated, Sponsor: Novo Nordisk A/S
Trial primary completion date: Dec 2014 --> Dec 2015 Active, not recruiting --> Terminated
- fletikumab (NNC109-0012) / Novo Nordisk
Trial termination: A Trial of NNC0109-0012, an Anti-IL-20 Biologic, in Patients With Active Rheumatoid Arthritis Who Are Inadequate Responders to Anti-TNFa Biologics (clinicaltrials.gov) - Nov 20, 2014
P2, N=239, Terminated, Sponsor: Novo Nordisk A/S
Active, not recruiting --> Terminated Active, not recruiting --> Terminated
- Clinical: Wireless Motion Sensors for Rheumatoid Arthritis Patients - Pilot Study (clinicaltrials.gov) - Nov 20, 2014
P=N/A, N=7, Not yet recruiting, Sponsor: Cedars-Sinai Medical Center
- fingolimod / Generic mfg.
Enrollment closed: Computerized Exercise Training for Cognitive Remediation in Adults With Multiple Sclerosis Treated With Gilenya (clinicaltrials.gov) - Nov 20, 2014
P=N/A, N=20, Active, not recruiting, Sponsor: Stony Brook University
Active, not recruiting --> Terminated Recruiting --> Active, not recruiting
- | Trial completion, Enrollment change, Trial primary completion date: Mindfulness Based Stress Reduction in Multiple Sclerosis (MS) (clinicaltrials.gov) - Nov 20, 2014
P=N/A, N=31, Completed, Sponsor: Stony Brook University
Recruiting --> Active, not recruiting Recruiting --> Completed | N=69 --> 31 | Trial primary completion date: Nov 2011 --> Apr 2013
- ||| Enbrel (etanercept) / Pfizer, Amgen
Enrollment change, Trial primary completion date: Study Conducted in Subjects With Rheumatoid Arthritis Who Have Moderate to Severe Disease Activity Despite Methotrexate Therapy With or Without Other Non Biologic Disease Modifying Antirheumatic Drugs (DMARDs)for at Least 12 Weeks Prior to Screening (clinicaltrials.gov) - Nov 20, 2014
P4, N=490, Recruiting, Sponsor: Pfizer
Recruiting --> Completed | N=69 --> 31 | Trial primary completion date: Nov 2011 --> Apr 2013 N=320 --> 490 | Trial primary completion date: Sep 2014 --> Mar 2015
- Plegridy (PEG-interferon ?-1a) / Biogen
Enrollment open: Study to Evaluate the Pharmacokinetic Profiles of BIIB017 (Peginterferon Beta-1a) and Rebif (clinicaltrials.gov) - Nov 20, 2014
P1, N=30, Recruiting, Sponsor: Biogen Idec
N=320 --> 490 | Trial primary completion date: Sep 2014 --> Mar 2015 Not yet recruiting --> Recruiting